News | December 07, 2021
Study shows Glaxo-Vir drug works against Omicron mutations
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
IIRSI 2021 aims to bring together ophthalmologists across India and abroad to discuss the advancement in technology and their experience in IOL implantation and Refractive Surgery
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes, as per WHO
The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
Subscribe To Our Newsletter & Stay Updated
